Navigation Links
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Date:8/3/2009

SAN DIEGO and DEERFIELD, Ill., August 3 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company and Astellas Pharma US, Inc. ("Astellas"), announced today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan injection) needle-free delivery system. Sumavel DosePro received FDA approval in July 2009 and is a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients.

"Partnering with Astellas is a significant milestone for Zogenix which will allow us to bring this cutting edge treatment to a broader number of people suffering from migraines," said Roger Hawley, CEO and director of Zogenix, Inc. "It was essential that we found the right partner for the introduction of our first product, Sumavel DosePro. Astellas will bring significant sales and marketing experience to our promotional efforts and help ensure the successful launch of Sumavel DosePro."

According to the National Headache Foundation, acute migraines affect nearly 30 million Americans, primarily women between the ages of 25 and 40, who are treated by primary care physicians and neurologists. Tablets are a treatment option for some of these migraine sufferers, but not all patients are satisfied with tablet therapy. Fast-acting, non-oral options are needed particularly for those who experience migraine episodes associated with sudden onset, waking, nausea or vomiting.

"Part of Astellas' corporate strategy is to continue establishing successful partnerships, so we are especially pleased to bring Sumavel DosePro to market with Zogenix," said Seigo Kashii, president and CEO of Astellas. "We believe this innovative product will have a broad appeal which complements our current primary care efforts and enriches our local portfolio. We look forward to our collaboration with Zog
'/>"/>

SOURCE Astellas Pharma US, Inc.; Zogenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Scientists Spot Brains Free Will Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a leading ... to present at the Jefferies 3rd Annual Healthcare Conference in New ... 2009. , , The presentations will be available to ... accessed by visiting http://investors.gentiva.com/events.cfm . Visitors ...
... ... New hope for a much needed new approach for tackling Alzheimer,s disease ... in Philadelphia. At the inaugural Targeting Alzheimer,s with Novel Therapeutics conference, ... Edward Tobinick MD, Director of the Institute for Neurological Research, a private ...
... Men Fly off the Shelves for Father,s Day , , ... for chronic lower back pain may lie in a $59.99 biomechanically-engineered ... be the turning point for the sixty million adults who reported ... shoe many claim to be a medical breakthrough is now available ...
... Inc. a technology and services company focused on global eClinical solutions ... 45th DIA Annual Meeting to be held later this month in ... well as a number of exciting new features and functionality in ... , Reaffirming our ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
... Over Half a Million Varicose Vein Patients Treated with VNUS Closure ... VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide ... venous reflux disease , the underlying cause of ... week, it estimates the number of patients treated with the VNUS ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 2Health News:New Immune Approach for Treatment of Alzheimer's Disease 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 4Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 3Health News:DATATRAK Announces New Products and Features at DIA San Diego 4Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:A Milestone of Opportunity for VNUS Medical Technologies 2Health News:A Milestone of Opportunity for VNUS Medical Technologies 3
(Date:12/22/2014)... DIEGO , Dec. 22, 2014  Pfenex Inc. ... Pfenex,s recombinant anthrax vaccine, has been filed and is ... funding provided by the Department of Health and Human ... Authority (BARDA). "We are extremely pleased to ... vaccine, Px563L.  This represents a significant milestone in our ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... , December 19, 2014 TODAY, ... in the World announced the appointment of Peter ... Vonsée, as Chief Channels and Partner Officer. ... 2004 through to its acquisition by Oracle in 2011. ... at Geneva and subsequently Convergys, ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
Bravo Vacuum Pump. Complete with tubing....
Stand with buffer tubes for calibration of Bravo pH capsule....
... lower esophhageal sphincter (LES) can ... a separate manometry system. pH ... identification accessory kit and Digitrapper ... locate the LES. The kit ...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
Medicine Products: